Vir Biotechnology Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Vir Biotechnology wird ein jährliches Gewinn- und Umsatzwachstum von 1% bzw. 32.2% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 5.5% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich -93.5% betragen.

Wichtige Informationen

1.0%

Wachstumsrate der Gewinne

5.5%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	28.4%
Wachstumsrate der Einnahmen	32.2%
Zukünftige Eigenkapitalrendite	-93.5%
Analystenabdeckung	Good
Zuletzt aktualisiert	20 Nov 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Earnings Update: Vir Biotechnology, Inc. (NASDAQ:VIR) Just Reported And Analysts Are Trimming Their Forecasts

Nov 04

Analysts Are Updating Their Vir Biotechnology, Inc. (NASDAQ:VIR) Estimates After Its Second-Quarter Results

Aug 03

Recent updates

Vir Biotechnology's Refocused Pipeline: Hepatitis And Oncology Could Still Pay Off

Nov 05

Earnings Update: Vir Biotechnology, Inc. (NASDAQ:VIR) Just Reported And Analysts Are Trimming Their Forecasts

Nov 04

Is Vir Biotechnology (NASDAQ:VIR) In A Good Position To Deliver On Growth Plans?

Sep 08

Analysts Are Updating Their Vir Biotechnology, Inc. (NASDAQ:VIR) Estimates After Its Second-Quarter Results

Aug 03

Bullish On Vir Biotechnology's Innovative Pipeline That Targets HIV And Hepatitis

Jul 17

Earnings Update: Vir Biotechnology, Inc. (NASDAQ:VIR) Just Reported And Analysts Are Boosting Their Estimates

May 05

Vir Biotechnology, Inc. (NASDAQ:VIR) Analysts Just Slashed This Year's Revenue Estimates By 37%

Aug 07

Revenues Working Against Vir Biotechnology, Inc.'s (NASDAQ:VIR) Share Price Following 42% Dive

Jul 24

Analysts Just Shaved Their Vir Biotechnology, Inc. (NASDAQ:VIR) Forecasts Dramatically

Feb 28

Vir Biotechnology, Inc. (NASDAQ:VIR) Shares Could Be 26% Below Their Intrinsic Value Estimate

Jan 07

Gewinn- und Umsatzwachstumsprognosen

NasdaqGS:VIR - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	34	-608	-544	-482	7
12/31/2025	33	-553	-498	-437	8
12/31/2024	75	-537	-434	-365	8
9/30/2024	79	-533	-473	-467	N/A
6/30/2024	79	-483	-459	-451	N/A
3/31/2024	80	-539	-779	-762	N/A
12/31/2023	86	-615	-800	-779	N/A
9/30/2023	119	-601	-668	-636	N/A
6/30/2023	491	-262	-410	-362	N/A
3/31/2023	446	-144	928	987	N/A
12/31/2022	1,616	516	1,595	1,663	N/A
9/30/2022	2,379	1,143	1,567	1,636	N/A
6/30/2022	2,108	1,078	1,357	1,412	N/A
3/31/2022	2,326	1,216	555	592	N/A
12/31/2021	1,095	529	-69	-48	N/A
9/30/2021	284	-102	-149	-137	N/A
6/30/2021	183	-297	-88	-81	N/A
3/31/2021	73	-390	-238	-232	N/A
12/31/2020	76	-299	-197	-191	N/A
9/30/2020	76	-257	-153	-148	N/A
6/30/2020	75	-220	-140	-135	N/A
3/31/2020	10	-223	-155	-149	N/A
12/31/2019	8	-175	-139	-130	N/A
9/30/2019	10	-137	-130	-120	N/A
6/30/2019	12	-122	-128	-118	N/A
3/31/2019	12	-117	-119	-109	N/A
12/31/2018	11	-116	-104	-94	N/A
12/31/2017	3	-70	N/A	-66	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: VIR wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: VIR wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: VIR wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: VIRDie Einnahmen des Unternehmens (32.2% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (9% pro Jahr).

Hohe Wachstumseinnahmen: VIRDie Einnahmen des Unternehmens (32.2% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: VIR wird voraussichtlich in 3 Jahren unrentabel sein.

Vir Biotechnology Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus EPS estimates fall by 18%

Price target decreased by 41% to US$18.43

Earnings Update: Vir Biotechnology, Inc. (NASDAQ:VIR) Just Reported And Analysts Are Trimming Their Forecasts

Price target increased by 8.2% to US$33.29

Consensus revenue estimates decrease by 18%, EPS upgraded

Analysts Are Updating Their Vir Biotechnology, Inc. (NASDAQ:VIR) Estimates After Its Second-Quarter Results

Recent updates

Vir Biotechnology, Inc. Presents Positive Chronic Hepatitis Delta Clinical Trial Data and Announces Initiation of Phase 3 Registrational Program

Vir Biotechnology, Inc. Announces Positive End-Of-T Treatment Results for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B from the March Study at AASLD The Liver Meeting

Consensus EPS estimates fall by 18%

New minor risk - Shareholder dilution

Vir Biotechnology's Refocused Pipeline: Hepatitis And Oncology Could Still Pay Off

Price target decreased by 41% to US$18.43

Earnings Update: Vir Biotechnology, Inc. (NASDAQ:VIR) Just Reported And Analysts Are Trimming Their Forecasts

New major risk - Revenue and earnings growth

Price target increased by 8.2% to US$33.29

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Vir Biotechnology, Inc. to Report Q3, 2024 Results on Oct 31, 2024

Vir Biotechnology, Inc. Announces Executive Appointments

Is Vir Biotechnology (NASDAQ:VIR) In A Good Position To Deliver On Growth Plans?

Consensus revenue estimates decrease by 18%, EPS upgraded

Analysts Are Updating Their Vir Biotechnology, Inc. (NASDAQ:VIR) Estimates After Its Second-Quarter Results

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Vir Biotechnology, Inc. to Report Q2, 2024 Results on Aug 01, 2024

Bullish On Vir Biotechnology's Innovative Pipeline That Targets HIV And Hepatitis

Vir Biotechnology, Inc.(NasdaqGS:VIR) dropped from Russell 2000 Value-Defensive Index

Vir Biotechnology, Inc. Receives FDA IND Clearance and Fast Track Designation for Tobevibart and Elebsiran for the Treatment of Chronic Hepatitis Delta Infection

New minor risk - Share price stability

Vir Biotechnology, Inc. Announces New Preliminary Data from its Phase 2 SOLSTICE Hepatitis Delta Clinical Trial Evaluating tobevibart, an Investigational Monoclonalantibody, and Elebsiran

Vir Biotechnology, Inc. Appoints Mark D. Eisner as Executive Vice President and Chief Medical Officer, Effective June 3, 2024

Consensus revenue estimates increase by 78%

Earnings Update: Vir Biotechnology, Inc. (NASDAQ:VIR) Just Reported And Analysts Are Boosting Their Estimates

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Vir Biotechnology Provides Some Hope For Its Beleaguered Shareholders

Vir Biotechnology, Inc., Annual General Meeting, May 29, 2024

Vir Biotechnology, Inc., Annual General Meeting, May 29, 2024

Vir Biotechnology, Inc. to Report Q1, 2024 Results on May 02, 2024

CEO & Director recently sold US$690k worth of stock

Vir Biotechnology Completes Enrollment of Phase 2 Chronic Hepatitis Delta SOLSTICE Trial Ahead of Schedule

Director notifies of intention to sell stock

Vir Biotechnology: Making Progress In Hepatitis B And Hepatitis Delta

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Director notifies of intention to sell stock

Price target increased by 12% to US$29.50

Vir Biotechnology, Inc. Announces Phil Pang Will Step Down as Chief Medical Officer

Price target decreased by 32% to US$18.00

Vir Biotechnology, Inc. to Report Q4, 2023 Results on Feb 22, 2024

Price target decreased by 10% to US$26.50

Sticking With Vir Biotechnology

Price target decreased by 9.2% to US$29.75

Price target decreased by 9.2% to US$29.75

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Vir Biotechnology, Inc. Appoints Jennifer Towne, Ph.D., as Executive Vice President and Chief Scientific Officer

Vir Biotechnology, Inc. Announces Multiple Abstracts Highlighting New Chronic Hepatitis B and Hepatitis Delta Data Accepted for Presentation at AASLD’s the Liver Meeting® 2023

Vir Biotechnology, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Biomedical Advanced Research and Development Authority Awards Funding to Vir Biotechnology, Inc. to Support Development of Antibody Platform Technologies for Global Infectious Disease Threats

Vir Biotechnology, Inc. Announces First Participant Dosed in New Phase 1 Trial Evaluating VIR-1388, an Investigational T Cell Vaccine for the Prevention of HIV

New major risk - Revenue and earnings growth

Vir Biotechnology, Inc. (NASDAQ:VIR) Analysts Just Slashed This Year's Revenue Estimates By 37%

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Vir Biotechnology, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Revenues Working Against Vir Biotechnology, Inc.'s (NASDAQ:VIR) Share Price Following 42% Dive

Consensus revenue estimates fall by 36%

Vir Biotechnology, Inc. Announces Topline Data from Phase 2 Peninsula Trial Evaluating VIR-2482 for the Prevention of Seasonal Influenza A Illness

Price target decreased by 24% to US$36.38

New minor risk - Share price stability

Independent Chairman notifies of intention to sell stock

Vir Biotechnology, Inc. Announces the Appointment of Sasha Damouni Ellis as Executive Vice President and Chief Corporate Affairs Officer, Effective July 10, 2023

Vir Biotechnology, Inc. Presents New Data Evaluating the Potential for VIR-2218 and VIR-3434 as Therapies for Chronic Hepatitis B and Hepatitis D

Independent Director notifies of intention to sell stock

Vir Biotechnology, Inc. Elects Elliott Sigal as Director

Vir Biotechnology, Inc. Appoints Jeff Calcagno, M.D., as Executive Vice President and Chief Business Officer

Vir Biotechnology, Inc. Announces First Patient Dosed in New Phase 2 Chronic Hepatitis B Virus Trial Evaluating Combinations of VIR-2218, VIR-3434, PEG-IFNa and an NRTI

Consensus EPS estimates fall by 12%, revenue upgraded

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Executive VP & Chief Technology Officer recently sold US$60k worth of stock